A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., prompting the Edmonton-based firm to establish a special committee to review the offer. Curaleaf Holdings Inc. disclosed its intention to purchase all shares of Aurora, aiming to create a combined cannabis enterprise with a presence in 17 countries spanning Europe, North America, and other global markets.
Curaleaf, headquartered in Stamford, Connecticut and listed on the Toronto Stock Exchange, decided to publicly announce its proposal after failed attempts to negotiate privately with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7 outlining the acquisition proposal, Aurora’s board allegedly declined to engage in discussions, according to Curaleaf.
Boris Jordan, Curaleaf’s CEO, expressed disappointment with Aurora’s lack of meaningful engagement and emphasized the significance of the proposed premium and strategic rationale. Jordan indicated that Curaleaf is prepared to directly approach Aurora shareholders to move forward with the transaction due to perceived delays in reaching a definitive agreement.
Curaleaf proposed a transaction offering Aurora shareholders $4 US per share along with an additional $0.75 US in cash for each share. Aurora confirmed receiving letters from Curaleaf on the specified dates but disputed Curaleaf’s claims of refusal to engage with the offer. The Canadian cannabis company clarified that ongoing communication between the parties had not been discouraged and that a special committee would evaluate the proposal’s alignment with stakeholders’ interests.
Despite Curaleaf’s interest, analysts from TD Cowen expressed reservations about the adequacy of the proposed consideration, suggesting that it undervalues Aurora’s long-term growth potential. The analysts highlighted Aurora’s market leadership in medical cannabis, diverse product portfolio, financial stability, and regulatory expertise as factors that could generate greater value over time.
Jordan highlighted the potential value creation from merging Curaleaf’s global distribution network with Aurora’s strong international medical cannabis operations and production capabilities. The combined revenue of both companies exceeded $1.5 billion US in the last year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed acquisition.
The merger was portrayed as mutually beneficial for Curaleaf and Aurora shareholders by providing access to a broader global platform and exposure to favorable U.S. regulatory trends, as stated by Jordan. The outcome of the bid remains uncertain, with Aurora continuing normal operations in the interim.